Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03152487 · ClinicalTrials.gov registry record · NA

Trial Comparing EUS-guided Radiofrequency Ablation vs. EUS-guided Celiac Plexus Neurolysis

A NA study of Pancreatic Cancer and Pancreatic Adenocarcinoma, sponsored by AdventHealth.

Completed
Registry status
NA
Development phase
28
Enrollment target
1
Study location

NCT03152487: Completed NA study of Pancreatic Cancer and Pancreatic Adenocarcinoma, sponsored by AdventHealth.

NCT03152487 is a NA study of Pancreatic Cancer and Pancreatic Adenocarcinoma that has completed, run by AdventHealth. The registered enrollment target is 28 participants, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03152487, a NA study of Pancreatic Cancer and Pancreatic Adenocarcinoma, has completed, sponsored by AdventHealth.

COMPLETED
Registry status
NA
Development phase
28 participants
Enrollment target
1
Study location

Study Summary

Pancreatic cancer is the second most common gastrointestinal malignancy. Abdominal discomfort is a main symptom in patients with pancreatic cancer. Approximately 75% have pain at diagnosis and over 90% in advanced stages. Pain control is an important part of the plan of care for patients with pancreatic cancer.. The celiac plexus is a group of nerves that supply organs in the abdomen. EUS-guided celiac plexus neurolysis (EUS-CPN) has been widely used for pain management in patients with pancreatic cancer. Radiofrequency ablation of celiac ganglia or celiac plexus (EUS-RFA) is also being performed to alleviate abdominal pain in pancreatic cancer patients. However currently no comparative studies exist comparing EUS-CPN with EUS-RFA. The purpose of the study is to compare EUS-CPN with EUS-RFA for pain management in pancreatic patients, in order to determine which technique is better at improving pain in pancreatic cancer patients.

Primary Outcome

Abdominal pain will be assessed with pain scores from the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Pancreatic Cancer module (QLQ-PAN26). The questionnaire has 26 questions with scoring ranging from a minimum of 26 to a maximum of 104. The higher the score, the worse the subject's quality of life rating.

Interventions

  • OTHER Celiac Plexus Neurolysis
  • OTHER Radiofrequency Ablation

Study Locations (1)

Florida

  • Center for Interventional Endoscopy - Florida Hospital - Orlando

Trial Details

FieldValue
Enrollment Target 28 participants
Start Date 2017-04-24
Est. Completion 2018-08-01
Phase NA
AdventHealth

95 total trials

What the finished NCT03152487 record still lists

NCT03152487 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 28 participants, a relatively small participant target, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (93% lower).

The record links to 5 conditions, with Pancreatic Cancer appearing as the primary indexed condition, and to 2 interventions - of which Celiac Plexus Neurolysis is the first listed.

NCT03152487 reports a single indexed study location in Florida.

Frequently Asked Questions

What is clinical trial NCT03152487 about?

NCT03152487 is a clinical study titled "Trial Comparing EUS-guided Radiofrequency Ablation vs. EUS-guided Celiac Plexus Neurolysis". Pancreatic cancer is the second most common gastrointestinal malignancy. Abdominal discomfort is a main symptom in patients with pancreatic cancer. Approximately 75% have pain at diagnosis and over 90% in advanced stages. Pain control is an important part of the plan of care for patients with pancre...

What is the current status of trial NCT03152487?

This trial is currently completed. It is a NA study. The enrollment target is 28 participants. The study started on 2017-04-24. Estimated completion is 2018-08-01.

What conditions does trial NCT03152487 study?

This clinical trial studies the following conditions: Pancreatic Cancer, Pancreatic Adenocarcinoma, Pancreatic Neoplasms, Pancreatic Cancer, Adult, Pancreatic Carcinoma Metastatic.

What interventions are being tested in trial NCT03152487?

The interventions under investigation include: Celiac Plexus Neurolysis (OTHER), Radiofrequency Ablation (OTHER).

Who is sponsoring clinical trial NCT03152487?

This trial is sponsored by AdventHealth, which has 95 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03152487 being conducted?

This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Pancreatic Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03152487's enrollment target sits among peer trials

28 199th of 278 higher than 76 of 278 other Pancreatic Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Pancreatic Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03471117 · 28 participants · Phase 4

    Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients

  • NCT03523975 · 28 participants · Phase 1

    Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma

  • NCT03608631 · 28 participants · Phase 1

    iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation

  • NCT03810651 · 28 participants · Early Phase 1

    Pencil Beam Scanning in Patients With Renal Tumors

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03152487, the US trial registry maintained by the National Library of Medicine. NCT03152487 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.